The Ferring Research Institute (FRI) in San Diego is Ferring Pharmaceuticals’ global research arm and ideas incubator. We collaborate across scientific and organizational frontiers to transform world-class science into life-changing medicines to save and transform lives.
Ferring Research Institute, United States
The Ferring Research Institute focuses on early drug discovery and drug development across our therapeutic areas from target identification to clinical proof-of-concept.
Ferring International Pharma Center, Copenhagen, Denmark
One of Ferring’s main research and development sites, this center houses Ferring Pharmaceutical’s bioanalysis, discovery biotherapeutics and immunology laboratories. As well as our preclinical & clinical development experts.
Bio-Technology General (BTG), Be’er Tuvia, Israel
BTG is a Ferring company focused on harnessing the power of biotechnology to build better, safe and essential biologics to improve patient’s lives.
Our Research centers
Our research institutes are strategically located throughout the world allowing Ferring access to key research ecosystems and attract world leading talent. Across the research centers we maintain a highly collaborative culture that encourages teams and individuals to work together across geographic boundaries.
“Pioneering the best science internally and externally has a long tradition within Ferring”
Our approach to early research and discovery
Within early research and discovery, we focus on what we do best: developing transformational medicines. We are determined to take an innovative research idea and turn it into a product that will help people live better lives. Our success is built on 70 years of innovation and commitment to patients.
Meet Araz Raoof, President of Ferring Research Institute and Senior Vice-President Global Drug Discovery & Eternal Innovation.
Our science is deeply interconnected, we are always open to new collaborations. We are proud to have a team of highly skilled and experienced scientists and technical experts leading our partnering process.
Latest jobs in research
Ferring looks for dedicated team members to join its research efforts around the world. We recruit the best and brightest at all levels of expertise.
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live BiotherapeuticMarch 24, 2022
New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body of ev...
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022March 11, 2022
Parsippany, NJ – May 11, 2022 – Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of rec...
Data for Ferring’s RBX2660 Published in BMC Infectious Diseases: “Durable Reduction of Clostridioides difficile Infection Recurrence and Microbiome Restoration after Treatment with RBX2660: Results from an Open-Label Phase 2 Clinical Trial”March 16, 2022
Primary objective was to compare treatment success of RBX2660 to historical control group A key secondary outcome was the safety profile of RBX2660 through 24 months after treatment Post hoc analys...